הממלכה המאוחדת - אנגלית - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharma uk ltd - ropinirole hydrochloride - oral tablet - 5mg

הממלכה המאוחדת - אנגלית - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - ropinirole hydrochloride - oral tablet - 5mg

הממלכה המאוחדת - אנגלית - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - ropinirole hydrochloride - oral tablet - 5mg

ארצות הברית - אנגלית - NLM (National Library of Medicine)

dispensing solutions, inc. - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 0.25 mg - parkinson’s disease ropinirole hydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic parkinson’s disease. the effectiveness of ropinirole hydrochloride tablets were demonstrated in randomized, controlled trials in patients with early parkinson’s disease who were not receiving concomitant l-dopa therapy as well as in patients with advanced disease on concomitant l-dopa (see clinical pharmacology: clinical trials). restless legs syndrome ropinirole hydrochloride tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). key diagnostic criteria for rls are: an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or n

ארצות הברית - אנגלית - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 0.25 mg - parkinson’s disease ropinirole hydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic parkinson’s disease. the effectiveness of ropinirole hydrochloride tablets were demonstrated in randomized, controlled trials in patients with early parkinson’s disease who were not receiving concomitant l-dopa therapy as well as in patients with advanced disease on concomitant l-dopa (see clinical pharmacology: clinical trials). restless legs syndrome ropinirole hydrochloride tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). key diagnostic criteria for rls are: an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or

ישראל - אנגלית - Ministry of Health

teva pharmaceutical industries ltd, israel - ropinirole as hydrochloride - film coated tablets - ropinirole as hydrochloride 0.25 mg - ropinirole - ropinirole - treatment of idiopathic parkinson's disease : ropinirole may be used alone in the treatment of idiopathic parkinson's disease.addition of ropinirole to levodopa may be used to control " on - off " fluctuations and permit a reduction in the total daily dose of levodopa.

ישראל - אנגלית - Ministry of Health

teva pharmaceutical industries ltd, israel - ropinirole as hydrochloride - film coated tablets - ropinirole as hydrochloride 2 mg - ropinirole - ropinirole - treatment of idiopathic parkinson's disease : ropinirole may be used alone in the treatment of idiopathic parkinson's disease.addition of ropinirole to levodopa may be used to control " on - off " fluctuations and permit a reduction in the total daily dose of levodopa.

ארצות הברית - אנגלית - NLM (National Library of Medicine)

alembic pharmaceuticals limited - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 0.25 mg - parkinson’s disease ropinirole tablets are indicated for the treatment of the signs and symptoms of idiopathic parkinson’s disease. the effectiveness of ropinirole tablets were demonstrated in randomized, controlled trials in patients with early parkinson’s disease who were not receiving concomitant l-dopa therapy as well as in patients with advanced disease on concomitant l-dopa (see clinical pharmacology: clinical trials). restless legs syndrome ropinirole tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). key diagnostic criteria for rls are: an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or night. difficulty falling asle

מלטה - אנגלית - Medicines Authority

lambda therapeutics limited sage house, 319, pinner road, north harrow, middlesex ha1 4hf, united kingdom - ropinirole - film-coated tablet - ropinirole 5 mg - anti-parkinson drugs

מלטה - אנגלית - Medicines Authority

lambda therapeutics limited sage house, 319, pinner road, north harrow, middlesex ha1 4hf, united kingdom - ropinirole - film-coated tablet - ropinirole 0.25 mg - anti-parkinson drugs